R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)

Phase 2

Completed

• Conditions: Lymphoma
• Interventions: Drug: rituximab, cyclophosphamide, vincristine, and prednisolone

• Registration Number: NCT01427114
• Lead Sponsor: Konkuk University Medical Center

Brief Summary

The purpose of this study is to determine how efficient the combination of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) is in the treatment of stage I or II non-conjunctival ocular adnexal MALT lymphoma (OAML).

Detailed Description

The treatment of stage I or II OAML is mainly composed of radiotherapy because chemotherapy including cyclophosphamide, vincristine, and prednisolone (CVP) did not show the acceptable response rate compared with radiotherapy. However, radiotherapy for this disease can cause many complications of eyes. This clinical trial was designed to examine the efficacy of R-CVP combination therapy as a first-line treatment for stage I or II non-conjunctival OAML aiming to avoid radiation hazard and increase the efficacy of CVP chemotherapy.

Study Timeline

• Study Start: 2011-07-01
• Study First Submitted: 2011-08-30
• Study First Submitted QC: 2011-08-30
• Study First Posted: 2011-09-01
• Primary Completion: 2014-08-01
• Study Completion: 2021-01-01
• Status Verified: 2021-05
• Last Update Submitted: 2021-05-03
• Last Update Posted: 2021-05-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

• Histologically confirmed OAML

• Non-conjunctival or bilateral conjunctival (TNM-based, above T1N0M0 or bT1N0M0), Ann Arbor stage I and II OAML

• Previously untreated

• Age ≥18 years

• Performance status: ECOG 0-2

• Adequate hematological function: hemoglobin ≥9 g/dL,, absolute neutrophil count (ANC) ≥1,500/μL, and platelet count ≥100,000/μL, unless abnormalities are due to bone marrow involvement by the lymphoma

• Adequate liver function tests:

  i. Transaminase (AST/ALT) <3 times the upper normal value ii. Bilirubin <2 times the upper normal value

• Adequate renal function:serum creatinine level <2 mg/dL (177 μmol/L)

• Life expectancy ≥ 6 months

• A negative serum or urine pregnancy test before treatment must be available for both premenopausal women and for women who have <2 years after the onset of menopause.

• Informed consent

Exclusion Criteria

• NHL subtypes other than OAML

• Primary conjunctival OAML, unilateral involved (T1N0M0)

• Ann Arbor stage III or IV

• CNS involvement by the lymphoma or any evidence of spinal cord compression. Brain CT/MRI is only mandatory (within 4 weeks) with clinical suspicion of CNS involvement by the lymphoma

• Pregnant or lactating women, women of child-bearing potential not using adequate contraception

• Inadequate liver function tests:

  i. Transaminase (AST/ALT) ≥3 times the upper normal value or ii. Bilirubin ≥2 times the upper normal value

• Inadequate renal function:

  i. serum creatinine level <2 mg/dL (177 μmol/L)

• Other serious illness or medical conditions i. Unstable cardiac disease despite treatment; myocardial infarction within 6 months prior to study entry ii. History of significant neurological or psychiatric disorders including dementia or seizures

• Active uncontrolled infection (HIV, hepatitis B, Hepatitis C, active Tuberculosis, active bacterial, or active fungal infection)

• Any other malignancies within the past 5 years except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri

• Known hypersensitivity to any of the study drugs or its ingredients (i.e., hypersensitivity to Polysorbate 20, CHO cell products, or recombinant human antibodies)

• Concomitant administration of any other experimental drug under investigation or concomitant chemotherapy, hormonal therapy, or immunotherapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
R-CVP	rituximab, cyclophosphamide, vincristine, and prednisolone	6 cycles of R-CVP followed by 2 cycles of rituximab

Primary Outcome Measures

Name	Time	Method
complete response rate	3 years	CR rate

Secondary Outcome Measures

Name	Time	Method
Overall survival	5 years	Overall survival
Number of Participants with Adverse Events as a Measure of Safety and Tolerability	5 years	Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Progression free survival	5 years	Progression free survival

Trial Locations

Locations (2)

Seoul St. Mary's Hospital; 🇰🇷 Seoul, Korea, Republic of

KonKuk University Medical Center; 🇰🇷 Seoul, Korea, Republic of